MX2023000610A - Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. - Google Patents
Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.Info
- Publication number
- MX2023000610A MX2023000610A MX2023000610A MX2023000610A MX2023000610A MX 2023000610 A MX2023000610 A MX 2023000610A MX 2023000610 A MX2023000610 A MX 2023000610A MX 2023000610 A MX2023000610 A MX 2023000610A MX 2023000610 A MX2023000610 A MX 2023000610A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- pharmaceutical composition
- relates
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 101150098315 TRPV4 gene Proteins 0.000 title abstract 3
- 208000030533 eye disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940126585 therapeutic drug Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 102000003567 TRPV4 Human genes 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052572P | 2020-07-16 | 2020-07-16 | |
| PCT/JP2021/026829 WO2022014707A1 (ja) | 2020-07-16 | 2021-07-16 | 眼疾患の治療薬としてのｔｒｐｖ４阻害薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000610A true MX2023000610A (es) | 2023-02-13 |
Family
ID=79555653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000610A MX2023000610A (es) | 2020-07-16 | 2021-07-16 | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230255965A1 (https=) |
| EP (1) | EP4183415A4 (https=) |
| JP (1) | JPWO2022014707A1 (https=) |
| KR (1) | KR20230041680A (https=) |
| CN (1) | CN115776890A (https=) |
| BR (1) | BR112022024553A2 (https=) |
| CA (1) | CA3189206A1 (https=) |
| MX (1) | MX2023000610A (https=) |
| TW (1) | TW202216143A (https=) |
| WO (1) | WO2022014707A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120641413A (zh) * | 2023-04-18 | 2025-09-12 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| WO2024217446A1 (zh) * | 2023-04-18 | 2024-10-24 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| WO2024217439A1 (zh) * | 2023-04-18 | 2024-10-24 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| CN116726013A (zh) * | 2023-04-25 | 2023-09-12 | 中国科学院大学深圳医院(光明) | Gsk2193874在防治痛性糖尿病周围神经病变中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409125A (en) | 1989-12-11 | 1995-04-25 | Aktiebolaget Astra | Unit dose container |
| DE4027320C2 (de) | 1990-08-29 | 1993-09-30 | Ursapharm Arzneimittel Gmbh | Fluid-Abgabeeinrichtung für keimfreies Fluid |
| EP0944530A1 (en) | 1996-12-09 | 1999-09-29 | Bausch & Lomb Incorporated | Single-use flexible container |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| TW586946B (en) | 2000-12-22 | 2004-05-11 | Novartis Ag | Process to improve stability |
| US20080139648A1 (en) | 2004-12-09 | 2008-06-12 | Santen Pharmaceutical Co., Ltd. | Product Containing Prostaglandin Having Fluorine Atom In Its Molecule |
| WO2007082262A2 (en) | 2006-01-11 | 2007-07-19 | Smithkline Beecham Corporation | Novel compounds |
| JP2009527495A (ja) | 2006-02-17 | 2009-07-30 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| JP5294601B2 (ja) | 2007-09-28 | 2013-09-18 | 小林製薬株式会社 | Ｔｒｐｖ４受容体抑制剤 |
| WO2009111680A1 (en) | 2008-03-07 | 2009-09-11 | Smithline Beecham Corporation | Trpv4 antagonists |
| WO2009146182A1 (en) | 2008-04-18 | 2009-12-03 | Smithkline Beecham Corporation | Trpv4 antagonists |
| WO2009146177A1 (en) | 2008-04-18 | 2009-12-03 | Smithkline Beecham Corporation | Trpv4 antagonists |
| WO2009139239A1 (ja) * | 2008-05-14 | 2009-11-19 | 日本電気株式会社 | 窒化物半導体レーザ及びその製造方法 |
| WO2010011912A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Trpv4 antagonists |
| JP5607046B2 (ja) | 2008-07-25 | 2014-10-15 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｔｒｐｖ４拮抗薬 |
| WO2011091407A1 (en) | 2010-01-25 | 2011-07-28 | Glaxosmithkline Llp | Trpv4 antagonists |
| WO2011091410A1 (en) | 2010-01-25 | 2011-07-28 | Glaxos Smithkline Llc | Trpv4 antagonists |
| WO2011119694A1 (en) | 2010-03-23 | 2011-09-29 | Glaxosmithkline Llc | Trpv4 antagonists |
| WO2011119693A1 (en) | 2010-03-23 | 2011-09-29 | Glaxosmithkline Llc | Trpv4 antagonists |
| WO2011119704A1 (en) * | 2010-03-23 | 2011-09-29 | Glaxosmithkline Llc | Trpv4 antagonists |
| WO2011119701A1 (en) | 2010-03-23 | 2011-09-29 | Glaxosmithkline Llc | Trpv4 antagonists |
| WO2012144661A1 (en) | 2011-04-20 | 2012-10-26 | Shionogi & Co., Ltd. | Aromatic heterocyclic derivative having trpv4-inhibiting activity |
| JO3154B1 (ar) | 2011-06-17 | 2017-09-20 | Glaxosmithkline Llc | عوامل مضادة لـ trpv4 |
| EP2720546B1 (en) | 2011-06-17 | 2016-04-06 | Glaxosmithkline Intellectual Property (No. 2) Limited | Spiro-cyclic trpv4 antagonists |
| US8927585B2 (en) | 2011-06-17 | 2015-01-06 | Glaxosmithkline Intellectual Property (No.2) Limited | TRPV4 antagonists |
| WO2013146754A1 (ja) | 2012-03-27 | 2013-10-03 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体 |
| CA2875842A1 (en) * | 2012-05-11 | 2013-11-14 | The University Of Utah Research Foundation | Compounds with trpv4 activity, compositions and associated methods thereof |
| WO2015046193A1 (ja) | 2013-09-25 | 2015-04-02 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体 |
| WO2015199206A1 (ja) | 2014-06-27 | 2015-12-30 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する６員環誘導体 |
| CN109153672B (zh) | 2016-05-19 | 2021-12-07 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Trpv4拮抗剂 |
| RU2019110821A (ru) | 2016-09-20 | 2020-10-22 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Антагонисты trpv4 |
| TW201825458A (zh) | 2016-09-20 | 2018-07-16 | 英商葛蘭素史克智慧財產（第二）有限公司 | Ｔｒｐｖ４拮抗劑 |
| JP2019532054A (ja) | 2016-09-20 | 2019-11-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｔｒｐｖ４拮抗薬 |
| MX2017011166A (es) | 2017-08-31 | 2019-03-07 | Univ Mexico Nac Autonoma | Uso de los farmacos antagonistas del canal ionico transient receptor potential vaniloid 4 (trpv4) para el tratamiento del edema macular. |
| JP7195067B2 (ja) | 2018-06-20 | 2022-12-23 | 花王株式会社 | ロズマリン酸誘導体又はその塩 |
| WO2021170811A1 (en) * | 2020-02-27 | 2021-09-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treating eye disease using trpv4 antagonists |
| JP7692219B2 (ja) * | 2020-04-30 | 2025-06-13 | ラクオリア創薬株式会社 | Ｔｒｐｖ４拮抗薬としてのピリミジン－４（３ｈ）－オン誘導体 |
-
2021
- 2021-07-16 JP JP2022536464A patent/JPWO2022014707A1/ja active Pending
- 2021-07-16 TW TW110126328A patent/TW202216143A/zh unknown
- 2021-07-16 KR KR1020237000435A patent/KR20230041680A/ko active Pending
- 2021-07-16 CA CA3189206A patent/CA3189206A1/en active Pending
- 2021-07-16 BR BR112022024553A patent/BR112022024553A2/pt unknown
- 2021-07-16 MX MX2023000610A patent/MX2023000610A/es unknown
- 2021-07-16 WO PCT/JP2021/026829 patent/WO2022014707A1/ja not_active Ceased
- 2021-07-16 EP EP21842049.5A patent/EP4183415A4/en active Pending
- 2021-07-16 CN CN202180045312.2A patent/CN115776890A/zh active Pending
- 2021-07-16 US US18/014,367 patent/US20230255965A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022024553A2 (pt) | 2023-01-24 |
| TW202216143A (zh) | 2022-05-01 |
| WO2022014707A1 (ja) | 2022-01-20 |
| US20230255965A1 (en) | 2023-08-17 |
| JPWO2022014707A1 (https=) | 2022-01-20 |
| EP4183415A4 (en) | 2024-07-17 |
| KR20230041680A (ko) | 2023-03-24 |
| EP4183415A1 (en) | 2023-05-24 |
| CN115776890A (zh) | 2023-03-10 |
| CA3189206A1 (en) | 2022-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
| US11207290B2 (en) | Combinations of cannabinoids and N-acylethanolamines | |
| US20130029989A1 (en) | Topical treatments for pain | |
| CN102470124B (zh) | 细胞保护剂 | |
| CA3048429A1 (en) | Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury | |
| CA2831054A1 (en) | Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury | |
| FI3840753T3 (fi) | Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio | |
| BR112021026369A2 (pt) | Derivados de 2h-indazol e seu uso no tratamento de doenças | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| WO2023227881A1 (en) | Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction | |
| WO2009003694A3 (en) | Method for treating diseases related to mitochondrial dysfunction | |
| MY200960A (en) | Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury | |
| Kuhad et al. | Neuroprotective effect of sesamol and quercetin against QA induced neurotoxicity: an experimental paradigm of Huntington's disease | |
| GB2619119A (en) | Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction | |
| Papapetropoulos et al. | Tardive dystonia associated with ziprasidone | |
| RU2010144554A (ru) | Средство для предотвращения и/или лечения сосудистых заболеваний | |
| Asadi-Pooya et al. | Potentiation of anti-epileptic drugs effectiveness by pyronaridine in refractory epilepsy | |
| Peterson et al. | Membrane stabilizers | |
| Abramowski | Chemotherapy-induced neuropathic pain | |
| Czlonkowska | THE CLINICAL DEVELOPMENT OF CEREBROLYSIN: NEW APPROACHES IN STROKE STUDIES. A COMMENTARY TO THE CARS STUDY | |
| Gould et al. | Effective long-term management of opioid-naive patients with oxymorphone extended release | |
| Kosinski et al. | Extent of physical, social and role activity limitations in Chronic Low Back Pain (CLBP) patients receiving opioid therapy: Results of an observational study | |
| EA201900418A1 (ru) | Средство для терапии раневых или ожоговых поражений кожи | |
| US20250352536A1 (en) | Neurorestoration compositions implementing multiple neuroplasticity inducing mechanisms of action |